Wells Fargo & Company Bio Line Rx Ltd. Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Wells Fargo & Company holds 35,035 shares of BLRX stock, worth $123,673. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35,035
Previous 56,035
37.48%
Holding current value
$123,673
Previous $31,000
41.94%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding BLRX
# of Institutions
39Shares Held
3.35MCall Options Held
46.5KPut Options Held
6.3K-
Alyeska Investment Group, L.P. Chicago, IL866KShares$3.06 Million0.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$2.88 Million4.05% of portfolio
-
Envestnet Asset Management Inc239KShares$844,3260.0% of portfolio
-
Morgan Stanley New York, NY198KShares$697,3050.0% of portfolio
-
Values First Advisors, Inc.166KShares$587,5640.02% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $217M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...